IE00B56GVS15 - Common Stock
ALKERMES PLC
NASDAQ:ALKS (7/26/2024, 7:16:02 PM)
After market: 27.88 0 (0%)27.88
-0.16 (-0.57%)
Alkermes Plc is a global biopharmaceutical company, which engages in the business of developing, manufacturing, and commercializing medicines designed to address unmet medical needs of patients in major therapeutic areas such as alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder, and a pipeline of product candidates in development for neurological disorders and cancer. The company is headquartered in Dublin, Dublin and currently employs 2,100 full-time employees. The firm has a portfolio of commercial products for the treatment of alcohol dependence, opioid dependence, schizophrenia and bipolar I disorder and a pipeline of clinical and preclinical candidates in development for neurological disorders. The company focuses on commercial products, such as LYBALVI, ARISTADA/ARISTADA INITIO and VIVITROL, and advancing the development of pipeline programs focused on neurological disorders. LYBALVI is a once-daily, oral atypical antipsychotic drug for the treatment of adults with schizophrenia and for the treatment of adults with bipolar I disorder, as a maintenance monotherapy or for the acute treatment of manic or mixed episodes, as monotherapy or an adjunct to lithium or valproate. ARISTADA is an extended-release intramuscular injectable suspension for the treatment of schizophrenia. The company has a manufacturing facility in Wilmington, Ohio.
ALKERMES PLC
Connaught House, 1 Burlington Road, Dublin 4
DUBLIN DUBLIN DUBLIN 4
P: 35317728000
CEO: Richard F. Pops
Employees: 2100
Website: https://www.alkermes.com/
ALKS stock results show that Alkermes beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Alkermes (NASDAQ:ALKS) just reported results for the second quarter of 2024.Alk...
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) today reported financial results for the second quarter of 2024. "Our second quarter results reflect solid...
/PRNewswire/ -- Alkermes plc (Nasdaq: ALKS) will host a conference call and webcast presentation at 8:00 a.m. ET (1:00 p.m. BST) on Wednesday, July 24, 2024 to...
Looking back at 30 five-stock samplers picked from 2015 to 2021.
Here you can normally see the latest stock twits on ALKS, but your cookie settings prevent this from loading. You can edit your cookie settings in our cookie consent dialog.
Example Twits: